We present results at 2 years follow-up of a group of 15 @entity1 with M  ni  re's disease treated with a low concentration of intratympanic @entity801 ( @entity70038 group), compared with a group of 15 @entity1 who refused any surgical treatment ( @entity5155 group). @entity70038 was administered according to a predetermined and fixed schedule consisting of 2 doses of 0.5 ml @entity801 solution, pH 7.8, injected once a week, with a drug concentration of 20 mg/ml; the total dose of @entity801 was < or = 20 mg. Additional doses of @entity70038 were administered only in @entity1 who had recurrence of vertigo. The results were evaluated following the American Academy of Otolaryngology Head and Neck Surgery 1995 criteria for reporting M  ni  re's disease treatment results by means of interviews, audiologic and vestibular evaluations, and a questionnaire based on a six-point functional level scale. Seven of the 15 @entity70038 @entity1 had recurrence of vertigo after the second injection and received a third dose of @entity70038 . Four @entity1 had recurrence of vertigo after the third infiltration; three subjects received a fourth dose and one refused additional injection. At 2 years follow-up, 93% of the @entity70038 @entity1 had complete (class A) or substantial (class B) control of vertigo. Only 47% of the @entity5155 @entity1 had no vertigo or were substantially improved. Hearing deteriorated in 7% of the @entity70038 group and in 40% of the @entity5155 group. @entity392 disappeared or improved in 20% of the @entity70038 @entity1 and in 27% of the @entity5155 @entity1 ; 40% of the @entity70038 @entity1 and 27% of the @entity5155 @entity1 reported that their aural pressure was abolished. The present study demonstrates that, in @entity1 with M  ni  re's disease, 0.5 ml doses of @entity801 solution, with a concentration of 20 mg/ml, injected intratympanically once a week minimize the risk of @entity393 in the treated ear, permitting complete control of vertigo in more than half of cases after 2 doses and in almost all subjects (93%) after 4 doses.

Intratympanic therapy for M  ni  re's disease: effect of administration of low concentration of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity801 :: ('MESH:D005839', 'Chemical') :: ['gentamicin'] @entity5155 :: ('MESH:C536394', 'Disease') :: ['NH'] @entity70038 :: ('MESH:C564643', 'Disease') :: ['IG'] @entity392 :: ('MESH:D014012', 'Disease') :: ['Tinnitus'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']
@entity801 :: (MESH:D005839,Chemical) :: ['gentamicin']
